Huaren Health released its performance for the first three quarters, with a net profit attributable to the parent company of 157 million yuan, an increase of 45.21%

According to the Zhitong Finance APP, Huaren Health released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 3.892 billion yuan, a year-on-year increase of 19.06%. The net profit attributable to shareholders of the listed company was 157 million yuan, a year-on-year increase of 45.21%. The net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 151 million yuan, a year-on-year increase of 51.00%. The basic earnings per share were 0.3918 yuan

Huaren Health: The application for the registration and marketing authorization of Furmaric Acid Voronol Tablets has been accepted

Huaren Health's wholly-owned subsidiary, Jiangsu Shenhua Pharmaceutical Co., Ltd., has received the acceptance notice for the drug registration application for Fumaric Acid Vonoprazan Tablets from the National Medical Products Administration. This new drug is a potassium ion competitive acid blocker that can effectively inhibit gastric acid secretion without relying on an acidic environment, significantly reducing the occurrence of nighttime gastric acid elevation

Huaren Health: The company prefers a prudent integration strategy rather than large-scale expansion

Huaren Health recently stated during an institutional research meeting that the company's management, based on strategic layout, prefers to adopt a prudent integration strategy: on one hand, focusing on developing chain franchise businesses; on the other hand, strengthening regional markets through small-scale acquisitions in already entered markets, rather than large-scale expansion. In the short term, the company will adopt a cautious approach to seize integration opportunities and continue to monitor market dynamics

Huaren Health released its performance for the first half of the year, with a net profit attributable to the parent company of 104 million yuan, an increase of 42.17%

According to the Zhitong Finance APP, Huaren Health released its semi-annual report for 2025, with operating revenue of 2.504 billion yuan, a year-on-year increase of 15.52%. The net profit attributable to shareholders of the listed company was 104 million yuan, a year-on-year increase of 42.17%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 101 million yuan, a year-on-year increase of 43.28%. The basic earnings per share were 0.2594 yuan

SPD concept stocks surged, Huaren Health hit the daily limit up of 20%, Winning Health rose over 10%, Chuangye Huikang and SYPM rose over 5%